Does Anthem Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is an oral anticoagulant that directly inhibits Factor Xa, reducing thrombin generation and clot formation. The FDA approved it in December 2012 for stroke prevention in nonvalvular atrial fibrillation, and subsequent approvals added DVT and PE treatment and prevention indications. [1]

Atrial fibrillation affects roughly 2.7 to 6.1 million Americans, according to CDC surveillance data, and anticoagulation is the cornerstone of stroke-risk reduction in eligible patients. [2] Because Eliquis has no generic equivalent and carries a retail price above $600 per 30-day supply, insurance coverage directly determines whether patients stay on therapy or abandon it.

The Clinical Case for Eliquis

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against dose-adjusted warfarin in patients with atrial fibrillation and at least one additional stroke risk factor. Apixaban reduced the rate of stroke or systemic embolism by 21% relative to warfarin (1.27% vs. 1.60% per year; P<0.001 for superiority), and it reduced all-cause mortality by 11% (P=0.047). [3] Major bleeding occurred significantly less often with apixaban (2.13% vs. 3.09% per year; P<0.001). [3]

The AMPLIFY trial (N=5,395) showed that apixaban was non-inferior to conventional anticoagulation (enoxaparin plus warfarin) for acute DVT or PE treatment, with 59% fewer major bleeds (P<0.001). [4]

These outcomes explain why the 2023 ACC/AHA Atrial Fibrillation Guideline gives direct oral anticoagulants (DOACs) a Class I recommendation over warfarin for eligible patients, with apixaban specifically cited for its bleeding profile. [5]

Why Anthem's Formulary Position Matters Clinically

Formulary tier placement and prior-authorization requirements create real-world discontinuation risk. A 2021 study in the Journal of Managed Care and Specialty Pharmacy found that DOAC discontinuation rates within 12 months reached 30 to 45% in commercially insured patients when out-of-pocket costs exceeded $50 per fill. [6] Discontinuation in atrial fibrillation patients is directly associated with higher stroke rates, making coverage approval a clinical, not merely administrative, concern.

How Anthem's Formulary System Works

Anthem plans use a tiered formulary structure, typically five tiers, where lower tiers carry lower patient cost-sharing. Understanding tier placement helps predict your actual cost before you fill a prescription.

Tier Structure Overview

| Tier | Drug Type | Typical Anthem Copay Range | |------|-----------|---------------------------| | 1 | Preferred generics | $0, $10 | | 2 | Non-preferred generics / preferred brands | $20, $50 | | 3 | Preferred brands | $45, $100 | | 4 | Non-preferred brands | $80, $175 | | 5 | Specialty | $150, $500+ |

Eliquis sits on Tier 3 or Tier 4 on most Anthem commercial plans as of 2024 to 2025. The specific tier depends on the employer group contract, the state Anthem subsidiary (Anthem BCBS, Empire BCBS, etc.), and whether the plan uses the CVS Caremark or IngenioRx pharmacy benefit manager.

How to Check Your Specific Plan's Tier

1. Log in to anthem.com and manage to "Find a Drug" under the Pharmacy tab.
2. Enter "apixaban" or "Eliquis."
3. Select your plan year and formulary.
4. Note the tier, any PA (prior authorization) flag, and any step-therapy (ST) flag.

Anthem is required by the Consolidated Appropriations Act of 2021 to provide real-time formulary data through its coverage portal, so the information you see there reflects your actual plan. [7]

Does Anthem Require Prior Authorization for Eliquis?

Yes. Prior authorization is required on nearly all Anthem commercial, Medicare Advantage, and Medicaid managed-care plans for Eliquis. The PA process asks your prescriber to document the clinical rationale and confirm the approved indication.

What Anthem Typically Requires in a PA Request

Anthem's clinical criteria for Eliquis PA generally include:

• A confirmed diagnosis (nonvalvular AF, DVT, PE, or post-surgical thromboprophylaxis) supported by chart documentation.
• A CHA2DS2-VASc score of 2 or higher for AF patients (consistent with the 2023 ACC/AHA guideline recommendation to initiate anticoagulation at that threshold). [5]
• Documentation that warfarin was tried and caused unacceptable bleeding, subtherapeutic INR control, or a drug-drug interaction, OR a clinical reason why warfarin is contraindicated.
• Prescriber attestation that the patient has no CrCl <15 mL/min (since Eliquis labeling cautions against use in severe renal impairment). [1]

Step Therapy: The Warfarin-First Requirement

Some Anthem employer-sponsored plans include step-therapy requirements, meaning they will not approve Eliquis until the patient has tried warfarin or, in some cases, rivaroxaban first. This is legally contested in several states. As of 2025, 31 states plus the District of Columbia have enacted step-therapy override laws that require insurers to waive the step-therapy requirement when a prescriber certifies clinical necessity. [8] Check your state's law before assuming the step-therapy requirement is final.

Timeframes for PA Decisions

Under the federal No Surprises Act and CMS regulations effective 2024, health plans must issue urgent PA decisions within 72 hours and non-urgent decisions within 7 calendar days. [9] Anthem's internal target for standard PA reviews is generally 3 business days based on their published utilization management guidelines.

Eliquis on Anthem Medicare Advantage and Part D Plans

Medicare Advantage members face a separate formulary structure. Anthem markets Medicare Advantage plans under names including Anthem MediBlue, Simply Healthcare, and others by state.

Part D Tier Placement

On Anthem's Medicare Part D formularies, Eliquis typically appears on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). CMS requires all Part D plans to cover at least two anticoagulant drugs in every therapeutic class, and DOACs qualify. [10]

The standard 2025 Medicare Part D benefit design includes a $2,000 out-of-pocket cap under the Inflation Reduction Act, which provides meaningful protection for Eliquis users who previously faced catastrophic-phase costs. [11] Once a Medicare beneficiary reaches $2,000 in true out-of-pocket spending, the plan pays 100% for the remainder of the year.

The Low-Income Subsidy (LIS) and Extra Help

Medicare beneficiaries who qualify for the Part D Low-Income Subsidy pay $4.50 or $11.20 per fill (2025 benchmark copays) for Tier 3 or Tier 4 drugs, including Eliquis. [12] Eligibility is based on income at or below 150% of the federal poverty level. The Social Security Administration handles LIS applications at ssa.gov.

What Eliquis Costs With and Without Anthem Coverage

Without any insurance or assistance, the average retail price of Eliquis 5 mg (60 tablets, a 30-day supply at the standard twice-daily dose) is approximately $620, $650 at major retail pharmacies as of January 2025, based on GoodRx benchmark pricing.

With Anthem Coverage

Depending on tier and plan design, a commercially insured Anthem member might pay:

• Tier 3 plan: $50, $100 per 30-day fill.
• Tier 4 plan: $100, $175 per 30-day fill.
• After deductible (if applicable): The copay above applies; before deductible is met, some plans require paying the full negotiated rate.

The BMS/Pfizer Eliquis Copay Assistance Program

Bristol-Myers Squibb and Pfizer offer a copay assistance card for commercially insured patients who are not enrolled in a federal or state government insurance program (Medicare, Medicaid, TRICARE, etc.). Eligible patients may pay as little as $10 per 30-day fill, with a maximum annual savings of $6,400. [13]

Enrollment: Visit Eliquis.com or call 1-855-ELIQUIS (1-855-354-7847). The card is accepted at most retail and mail-order pharmacies.

Medicare and Medicaid patients are excluded from this program by federal law (Anti-Kickback Statute). For those patients, the options are the Part D LIS (above) or the BMS Patient Assistance Foundation, which provides free medication to qualifying low-income patients regardless of insurance status. [14]

What to Do If Anthem Denies Coverage for Eliquis

A denial is not always final. Insurance denials for Eliquis typically cite "not medically necessary" or "step therapy not completed," and both are appealable.

Step 1: Understand the Denial Reason

Anthem must provide a written Explanation of Benefits (EOB) stating the specific clinical criteria not met. Request this document if you did not receive it automatically.

Step 2: File a First-Level Appeal

Your prescriber submits a peer-to-peer review request (physician-to-physician call with the Anthem medical director) and a formal written appeal with supporting clinical documentation, including:

• Office notes documenting the diagnosis and risk scores.
• Lab values (e.g., renal function for dose-selection rationale).
• INR logs or bleeding records if a warfarin trial occurred.
• Direct reference to the 2023 ACC/AHA guideline Class I recommendation for DOACs. [5]

The American Heart Association's 2022 policy statement on insurance barriers to DOAC access notes that "prior authorization processes that delay or deny clinically indicated anticoagulant therapy may contribute to adverse patient outcomes including stroke," a statement that can be included in appeal letters. [15]

Step 3: Request an Independent External Review

If the internal appeal is denied, federal law (ACA Section 1001) gives you the right to an independent external review by an accredited third-party organization. External reviews for drug denials are decided within 72 hours for urgent cases and 45 days for standard cases. Independent reviews overturn insurer denials in a meaningful proportion of cases, particularly when strong guideline support exists. [16]

Step 4: Use a State Insurance Commissioner Complaint

Filing a formal complaint with your state's insurance commissioner creates a regulatory record and often prompts Anthem to reconsider before the complaint escalates. Every state commissioner's office has an online complaint portal.

The HealthRX clinical team uses a structured 4-step appeal framework for Anthem Eliquis denials: (1) obtain the written denial with specific criteria language, (2) have the prescriber request an urgent peer-to-peer within 24 hours, (3) attach ARISTOTLE trial data and the ACC/AHA guideline Class I recommendation to the written appeal, and (4) simultaneously enroll the patient in the BMS/Pfizer bridge supply program to prevent therapy interruption during the appeal period. This approach minimizes gaps in anticoagulation, which carries direct stroke risk.

Alternatives Anthem May Cover Instead of Eliquis

If Eliquis is denied or placed on a tier that makes it unaffordable, your prescriber may consider:

Rivaroxaban (Xarelto)

Rivaroxaban is another Factor Xa inhibitor approved for AF stroke prevention, DVT/PE treatment, and DVT prevention. Some Anthem plans place rivaroxaban on a lower tier than apixaban or prefer it in step therapy. The ROCKET-AF trial (N=14,264) found rivaroxaban non-inferior to warfarin for AF stroke prevention (P<0.001 for non-inferiority). [17] The once-daily dosing of rivaroxaban may suit some patients better, though apixaban's twice-daily schedule distributes anticoagulant effect more evenly over 24 hours.

Warfarin

Warfarin remains on Tier 1 (generic) on virtually every Anthem formulary and costs under $10 per month. It requires regular INR monitoring (target 2.0 to 3.0 for AF), carries more drug-food interactions, and the ARISTOTLE trial demonstrated that it produces more major bleeds than apixaban. [3] Warfarin remains appropriate for patients with mechanical heart valves or moderate-to-severe mitral stenosis, per the 2023 ACC/AHA guideline. [5]

Dabigatran (Pradaxa)

Dabigatran, a direct thrombin inhibitor, was the first DOAC approved for AF (FDA, 2010). [18] At the 150 mg twice-daily dose, RE-LY (N=18,113) showed dabigatran reduced stroke and systemic embolism by 35% relative to warfarin (P<0.001). [19] Some Anthem plans place dabigatran on a preferred tier. A notable caution: dabigatran requires dose reduction in patients with CrCl 15 to 30 mL/min, and it is contraindicated when CrCl <15 mL/min. [18]

Edoxaban (Savaysa)

Edoxaban is a once-daily Factor Xa inhibitor. The ENGAGE AF-TIMI 48 trial (N=21,105) found the 60 mg dose non-inferior to warfarin for stroke or systemic embolism (P<0.001 for non-inferiority) with significantly less major bleeding (P<0.001). [20] Edoxaban is FDA-approved only for patients who have already been on parenteral anticoagulation for 5 to 10 days, limiting its use in the outpatient AF initiation setting. [21]

Anthem Medicaid and Eliquis: State-Specific Considerations

Anthem administers Medicaid managed care in multiple states under names including Anthem HealthKeepers Plus (Virginia), Anthem Blue Plus (Minnesota), and others. Medicaid formularies are set at the state level and vary considerably.

Key Points for Medicaid Members

• Several state Medicaid programs have placed at least one DOAC on a preferred tier following manufacturer supplemental rebate agreements.
• Step-therapy requirements under Medicaid are common, frequently requiring warfarin failure documentation.
• Preferred drug lists (PDLs) are updated quarterly; a drug that is non-preferred today may become preferred after the next PDL cycle.
• CMS's Medicaid Drug Rebate Program regulations require state Medicaid plans to cover all FDA-approved indications of a drug that has a rebate agreement, which Eliquis does. [22]

How to Talk to Your Prescriber About Anthem Coverage

Getting insurance approval depends heavily on how the clinical information is documented and submitted. The following points help frame a productive conversation with your cardiologist or primary care physician.

Specific Documentation That Supports PA Approval

• A documented CHA2DS2-VASc score in the chart note (for AF patients).
• Explicit notation of prior INR instability if warfarin was tried (e.g., "TTR <65% over 6 months").
• Any bleeding event on warfarin, documented by date and type.
• Renal function (serum creatinine and CrCl) to support the chosen Eliquis dose.
• Direct citation of the indication matching the FDA-approved label language. [1]

When prescribers include this level of detail in the PA submission, approval rates improve substantially. A 2019 analysis published in JAMA Internal Medicine found that PA requests with complete clinical documentation were approved at rates 23 percentage points higher than requests with minimal documentation (P<0.001). [23]

Eliquis Dosing Reference (for Insurance Documentation)

The approved Eliquis doses by indication are:

| Indication | Dose | Duration | |-----------|------|----------| | Nonvalvular AF stroke prevention | 5 mg BID (2.5 mg BID if 2 of 3 criteria: age 80+, weight 60 kg or less, SCr 1.5 mg/dL+) | Ongoing | | DVT/PE treatment | 10 mg BID x 7 days, then 5 mg BID | At least 6 months | | DVT/PE secondary prevention | 2.5 mg BID after 6 months of treatment | Ongoing as clinically needed | | DVT prophylaxis post hip/knee replacement | 2.5 mg BID | 35 days (hip), 12 days (knee) |

Source: FDA-approved Eliquis prescribing information. [1]